Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
Wednesday, June 1, 2011 - 14:00
in Health & Medicine
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox Chase Cancer Center researchers report that a combination of two molecularly-targeted agents may provide similar therapeutic benefit with less toxicity.